Extending their collaboration, Genialis and Debiopharm continue working towards a patient classifier to support WEE1 clinical development Genialis, the RNA biomarker company, today announced an ...

Genialis and Debiopharm expand collaboration to develop RNA-based predictive biomarkers for DDR therapies, advancing precision oncology.

A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will ...

The global immunohistochemistry (IHC) market is expected to grow from USD 3.5 billion in 2024 to USD 7.4 billion by 2034, reflecting a CAGR of 7.8% over the forecast period. Request a Sample Copy of ...

BOSTON--(BUSINESS WIRE)--Genialis, the RNA biomarker company, today announced an extension of its collaboration with Debiopharm, a Swiss-based global biopharmaceutical company, to develop a ...

New University of Virginia School of Medicine research revealing the fingerprints of Sudden Infant Death Syndrome (SIDS) ...

Proteome Sciences plc (LON:PRM – Get Free Report)’s stock price crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of GBX 3.35 ($0.04) and ...

The study identified gene expression changes which were detected beginning three months after intranasal dosing of foralumab in our ongoing ISPPEA (or expanded access program). Key findings include ...

Tiziana Life Sciences announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) who were treated with intranasal foralumab ...

PathAI, a leading provider of AI-powered technology for pathology, today announced a strategic partnership with Discovery Life Sciences, a leading biospecimens and specialty lab testing company, to ...